Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 3 1

Status

Completed 4Active not recruiting 2Terminated 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 7

Sponsor

Cancer Type

Head & Neck 23Thoracic 13Gastrointestinal 10Dermatologic 8Tumor-Agnostic 7Genitourinary 7Breast 6Gynecologic 5Sarcoma 3Lymphoid 3Other solid neoplasm 1CNS 1

Conditions

Neoplasms 56Neoplasm Metastasis 34Carcinoma 7Adenocarcinoma 7Carcinoma, Squamous Cell 6Neoplasms, Unknown Primary 2

Interventions

Paclitaxel 9Carboplatin 9pembrolizumab 7Radiotherapy 7Cisplatin 5Axitinib 4Pemetrexed 3Nivolumab 3trifluridine tipiracil drug combination 2regorafenib 2osimertinib 2fludarabine 2dacomitinib 2catumaxomab 2Trastuzumab 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Nurses 2Interleukin-2 2Gemcitabine 2Docetaxel 2Cyclophosphamide 2Cetuximab 2Bevacizumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vatalanib 1temsirolimus 1sovateltide 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Carcinoma × pembrolizumab × Tumor-Agnostic × Clear all
NCT03752333 2026-05-04

CUPem

Imperial College London

Phase 2 Completed
35 enrolled 11 charts
Tumor-Agnostic

Carcinoma, Neoplasms, Neoplasms, Unknown Primary

NCT05349890 2026-04-24

Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Providence Health & Services

Phase 1 Active not recruiting
1 enrolled
Tumor-Agnostic

Carcinoma

NCT04520711 2026-04-13

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Providence Health & Services

Phase 1 Active not recruiting
24 enrolled
Tumor-Agnostic

Carcinoma

NCT03976362 2026-02-25

KEYLYNK-008

Merck Sharp & Dohme LLC

Phase 3 Completed
851 enrolled 25 charts
Tumor-Agnostic

Carcinoma

NCT05165433 2025-12-16

FORTIFY

Akamis Bio

Phase 1 Completed
14 enrolled
Tumor-Agnostic

Carcinoma, Neoplasm Metastasis

NCT03396471 2024-04-18

Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary

Hoosier Cancer Research Network

Phase 2 Terminated
14 enrolled 17 charts
Tumor-Agnostic

Carcinoma

NCT02883556 2021-01-13

CARSKIN

Assistance Publique - Hôpitaux de Paris

Phase 2 Completed
57 enrolled
Tumor-Agnostic

Carcinoma, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡